gene

ALPHA-SYNUCLEIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALPHA-SYNUCLEIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1819Connections

3Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

ALPHA-SYNUCLEIN is a gene implicated in neurodegeneration research. Key relationships include: associated with, activates, therapeutic target. Associated with ALS, Aging, Als. Connected to 529 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	ALPHA
Full Name	SYNUCLEIN
Chromosome	4q21.31
Protein Family	Synuclein family
Subcellular Localization	Presynaptic terminals, nucleus
Molecular Weight	14 kDa (140 aa)
Pathways	amyloid plaques, mTORC1, oxidative stress
UniProt ID	P37840
GeneCards	ALPHA
Human Protein Atlas	ALPHA
Associated Diseases	ALS, Aging, Alzheimer, Alzheimer's Disease, Ataxia
Known Drugs/Compounds	FINGOLIMOD, RAPAMYCIN, LITHIUM, proCTSD, DEXAMETHASONE
Interactions	INFLAMMATION, PHAGOCYTOSIS, LC3, PARKIN, LRRK2, OXIDATIVE STRESS
KG Connections	1167 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🔮 Predicted Structure: ALPHA-SYNUCLEIN — AlphaFold P37840 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| PARKINSON_S_DISEASE["PARKINSON'S DISEASE"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"activates"| INFLAMMATION["INFLAMMATION"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| ALS["ALS"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| SOD1["SOD1"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| DRD2["DRD2"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| AQP4["AQP4"]
    PARKIN["PARKIN"] -->|"regulates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    PARKINSON_S_DISEASE_1["PARKINSON'S DISEASE"] -->|"regulates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    MICROGLIA["MICROGLIA"] -->|"activates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    PARKINSON_S_DISEASE_2["PARKINSON'S DISEASE"] -->|"associated"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    style ALPHA_SYNUCLEIN fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1016)

Target	Relation	Type	Str
Parkinson	associated_with	disease	1.00
Parkinson	therapeutic_target	disease	1.00
Neurodegeneration	activates	disease	1.00
Parkinson	activates	disease	1.00
Inflammation	activates	disease	1.00
PARKINSON'S DISEASE	associated_with	gene	0.95
Als	associated_with	disease	0.95
Neurodegeneration	therapeutic_target	disease	0.95
Als	activates	disease	0.95
Synucleinopathies	causes	disease	0.95
Parkinson's Disease	involved_in	disease	0.95
Parkinson's Disease	associated_with	disease	0.95
Diffuse Lewy Body Disease	involved_in	disease	0.95
Multiple System Atrophy	involved_in	disease	0.95
Lewy Bodies	component_of	structure	0.95
NEURON	contributes_to	cell_type	0.95
DOPAMINERGIC NEURONS	contributes_to	cell_type	0.95
Neuroinflammation	causes	process	0.90
Chaperone Proteins	correlates_with	protein	0.90
Autophagy	activates	pathway	0.90
NEURON	interacts_with	cell_type	0.86
Parkinson	regulates	disease	0.85
Aging	therapeutic_target	disease	0.85
Alzheimer	activates	disease	0.85
Neurodegeneration	regulates	disease	0.85
Neuronal Dysfunction	causes	phenotype	0.85
Inflammation	modulates	process	0.85
Glial Reactivity	regulates	process	0.85
Neuroinflammation	activates	disease	0.85
Inflammation	associated_with	disease	0.85
Parkinson's Disease	biomarker_for	disease	0.85
Cognitive Function	regulates	phenotype	0.85
Alzheimer's Disease	associated_with	disease	0.85
Ros/Rns	associated_with	process	0.85
NEURON	expressed_in	cell_type	0.85
INFLAMMATION	activates	gene	0.80
Microglia Activation	activates	cell_type	0.80
Astrocyte Activation	modulates	cell_type	0.80
Microglia	activates	cell_type	0.80
DOPAMINERGIC NEURONS	depletes	cell_type	0.80
Parkinson's disease	causes	disease	0.80
DISTINCT CLINICAL PHENOTYPES	associated_with	phenotype	0.80
Parkinson's disease	implicated_in	disease	0.80
NEURONS	causes	cell_type	0.80
Oxidative Stress	associated_with	pathway	0.80
MICROGLIA	activates	gene	0.80
NEUROINFLAMMATION	activates	gene	0.80
Stem Cell	activates	pathway	0.80
NEUROINFLAMMATION	associated_with	gene	0.75
Als	interacts_with	disease	0.75

Incoming (803)

Source	Relation	Type	Str
PARKINSON'S DISEASE	associated_with	gene	1.00
PARKINSON'S DISEASE	therapeutic_target	gene	1.00
PARKINSON'S DISEASE	activates	gene	1.00
NEURODEGENERATION	activates	gene	1.00
PARKINSON	associated_with	gene	1.00
PARKINSON	therapeutic_target	gene	1.00
PARKIN	regulates	gene	0.95
SNCA	encodes	gene	0.95
INFLAMMATION	activates	gene	0.90
NEURODEGENERATIVE DISEASES	associated_with	gene	0.90
PARKINSON	activates	gene	0.90
NEURON	activates	cell_type	0.86
NEURON	interacts_with	cell_type	0.86
HSPG2	promotes_aggregation_of	gene	0.80
proCTSD	targets	drug	0.80
MICROGLIA	extracts	cell_type	0.80
PARKINSON	regulates	gene	0.80
NEURODEGENERATION	regulates	gene	0.80
AMYLOID	associated_with	gene	0.80
OXIDATIVE STRESS	associated_with	gene	0.80
ASTROCYTES	activates	gene	0.80
SNCA	causes	gene	0.80
TAU	associated_with	gene	0.80
NEURODEGENERATION	therapeutic_target	gene	0.80
SNCA	interacts_with	gene	0.72
MICROGLIA	interacts_with	cell_type	0.72
NEURODEGENERATION	causes	gene	0.70
AMPK	activates	gene	0.70
PARKINSON	interacts_with	gene	0.70
AMYLOID-BETA	associated_with	gene	0.70
LRRK2	activates	gene	0.70
ALZHEIMER	activates	gene	0.70
CYTOKINES	activates	gene	0.70
ALZHEIMER	associated_with	gene	0.70
AUTOPHAGY	activates	gene	0.70
NEURODEGENERATIVE DISEASES	activates	gene	0.70
NURR1	activates	gene	0.70
NEURODEGENERATIVE DISORDERS	associated_with	gene	0.70
ASTROCYTE	transports	cell_type	0.70
APP	activates	gene	0.70
DOPAMINE	activates	phenotype	0.70
INFLAMMATION	exacerbates	phenotype	0.70
ROS	treats	phenotype	0.70
TAU	modifies	protein	0.70
DEXAMETHASONE	inhibits	drug	0.65
DEXAMETHASONE	activates	drug	0.65
LRRK2	regulates	gene	0.65
AUTOPHAGY	treats	phenotype	0.65
VCP	phosphorylates	gene	0.65
GDNF	activates	gene	0.65

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.599	neurodegeneration	What are the mechanisms by which gut mic
H7: Enteric Nervous System Alpha-Synuclein Propagation Block	0.595	neurodegeneration	How does engineered C. butyricum cross t
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali	0.382	neurodegeneration	Which cell types show the most significa

Mentioning Analyses (2)

Scientific analyses that reference this entity

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

neurodegeneration | 2026-04-13 | 0 hypotheses

GBA-Synuclein Loop Therapeutics for PD

neurodegeneration | 2026-04-01 | 0 hypotheses

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391]	Lin Aung T, Aung YW, Shi X	Biomed Phys Eng Express	2026	1
A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647]	Tran HD, Shin MK, Yeo XY, Jung S, Junaid	Brain	2026	0
Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593]	Boyd RJ, Kho AR, McClymont SA, Loftus SK	Brain	2026	0
Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763]	Ueda J, Uemura N, Chang J, Hirato T, Ish	Mov Disord	2026	0
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889]	Fraser KB, Mirelman A, Mabrouk OS, Omer	J Parkinsons Dis	2026	0
Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116]	Wang Y, Lipton SA	J Neurochem	2026	0
SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927]	Statoulla E, Zafeiri M, Chalkiadaki K, V	NPJ Parkinsons Dis	2026	0
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496]	Panda SP, Saraswat N, Singh V	Neuroscience	2026	0
Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943]	Kabuta C, Hakuno F, Kataoka N, Takahashi	Neurochem Int	2026	0
An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745]	Asmi S, Krishnan A, Alexander SM, Mohame	Ageing Res Rev	2026	0
N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663]	Song P, Chen C, Franchini R, Duong B, Wa	J Clin Invest	2026	0
Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621]	["Singh R", "Maity P", "Jaiswal C"]	Neurochemistry international	2026	0

ALPHA-SYNUCLEIN

Understanding Entity Pages

Summary

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

Neuroresilience Mechanisms and Evidence

Therapeutics

NPM1 Gene